Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CTDC moving quick in pre.
CHNR is sick. damn
LUM getting some action.eom
Geez, run up in AH too.
See anything on CHNR??
Covered CPSL 7.49. Hit my buy stop this AM while at work.
Short some CPSL 10.80.eom
EFUT on a tear.eom
I got alliance trader. None of your brokers are showing any available?
I'm seeing shares available to me and that makes me very leary. Usually can't get shares when you really want them(at the top).
Any thoughts on the latest pump CRDC?
Any1 see news on TARR?
TARR eod run.
Out CRDC for now, that damn $9!
In CRDC 8.75
Check out CRDC
Out PFSW 1.52.
In PFSW @ 1.37.eom
All is not lost just yet:
Accredited Disputes Lone Star Assertion of Failure of Condition
Last Update: 9:49 PM ET Aug 10, 2007
SAN DIEGO, Aug 10, 2007 (BUSINESS WIRE) -- Accredited Home Lenders Holding Co. (LEND :
accredited home lendrs hldg com
News , chart , profile , more
Last: 8.91+2.78+45.27%
8:10pm 08/10/2007
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
LEND8.91, +2.78, +45.3% ) ("Accredited" or "Company") today announced that it believes all conditions to the closing of the pending tender offer for Accredited's common stock will be satisfied by the expiration of the current tender offer period, and that Accredited strongly disagrees with the statement made by affiliates of Lone Star Fund V (U.S.), L.P. ("Lone Star") that, as of today, Accredited would fail to satisfy the conditions to the closing of the tender offer. The statement was made in an August 10, 2007 filing by Lone Star with the Securities and Exchange Commission in which Lone Star also said that it does not expect to accept Accredited shares tendered as of the end of the current offer period ending at 12:00 midnight, Eastern time, on August 14, 2007.
Accredited noted that it had entered into an agreement that would resolve the class action lawsuit which had sought to enjoin the closing of the tender offer, Wan vs. Accredited Home Lenders Holding Co., et al., and that, as previously announced, all state regulatory approvals required to close the tender offer had been obtained. Accredited explained that, earlier in the day, both it and Lone Star had entered into a Memorandum of Understanding (the "Memorandum") with the plaintiff in the Wan case. The Memorandum outlines a proposed settlement that is subject to court approval, but the Memorandum is structured in such a manner that the tender offer can be completed prior to the court's decision with respect to the proposed settlement.
With the receipt of all required regulatory approvals and the resolution of the Wan litigation, Accredited believes that, assuming more than 50% of Accredited's outstanding shares are tendered by the expiration of the current tender offer period on August 14, 2007, all conditions to closing of the tender offer will have then been satisfied.
Accredited noted that the Agreement and Plan of Merger with Lone Star expressly provides that changes generally affecting the non-prime industry in which the Company operates which have not disproportionately affected the Company do not provide a basis for Lone Star to not honor its obligations. Accredited said that it intends to hold Lone Star to its obligations, and to hold it fully responsible for any damages caused by its failure to satisfy those obligations.
About Accredited
Accredited Home Lenders Holding Co. is a mortgage company operating throughout the U.S. and in Canada. Accredited originates, finances, securitizes, services, and sells non-prime mortgage loans secured by residential real estate. Founded in 1990, the company is headquartered in San Diego. Additional information may be found at www.accredhome.com.
About Lone Star Funds
Lone Star is a leading U.S. private equity firm. Since 1995, the principals of Lone Star have organized private equity funds totaling more than $13.3 billion to invest globally in corporate secured and unsecured debt instruments, real estate related assets and select corporate opportunities. Additional information may be found at www.lonestarfunds.com.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. These forward-looking statements involve a number of risks and uncertainties, including the Company's ability to close the proposed merger with Lone Star, and other risk factors as outlined in Accredited Home Lenders Holding Co.'s annual report on Form 10-K for the year ended December 31, 2006, and other documents filed by the Company with the Securities and Exchange Commission. These and other factors could cause the Company's actual results to differ materially from what it projects or contemplates in its forward-looking statements. The Company cautions readers that the non-prime mortgage industry and the Company's business are subject to numerous significant risks and uncertainties.
SOURCE: Accredited Home Lenders Holding Co.
http://www.marketwatch.com/news/story/accredited-disputes-lone-star-assertion/story.aspx?guid=%7BC3E...
AHM eod WOW. D U M P.
Did anyone see that go to 4.60??? i was on the phone and I just can't believe it.
Anyone playing AHM? Saw it in pre around 1.50 and went on to PHRM.
AHM looking to break $2.eom
PHRM gapping hard on this news:
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Two year survival rate of 50.8 percent for Vidaza versus 26.2 for conventional care regimens 9.4 months median survival benefit for patients on Vidaza compared to conventional care regimens Only agent to demonstrate survival benefit in MDS compared to conventional care regimens Only epigenetic modifier to show survival benefit in cancer Stratified log-rank p-value = 0.0001, Hazard ratio = 0.58 Largest study ever conducted in higher-risk MDS
Last Update: 8:26 AM ET Aug 2, 2007
BOULDER, Colo., Aug 02, 2007 /PRNewswire-FirstCall via COMTEX/ -- Pharmion Corporation (PHRM :
pharmion corp com
News , chart , profile , more
Last: 24.64+0.28+1.15%
8:40am 08/02/2007
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
PHRM24.64, +0.28, +1.1% ) today announced topline results from the multi-institutional, international, randomized, Phase 3 controlled trial of Vidaza(R) (azacitidine for injection) versus conventional care regimens (CCR) in the treatment of patients with higher-risk myelodysplastic syndromes (MDS). In the primary endpoint analysis, Vidaza treatment was associated with a median survival of 24.4 months versus 15 months for those receiving CCR treatment, an improvement of 9.4 months with a stratified log-rank p-value of 0.0001. The hazard ratio describing this treatment effect was 0.58 (95 percent confidence interval of 0.43 to 0.77). Two-year survival rates were 50.8 percent versus 26.2 percent for patients receiving Vidaza versus CCR (p<0.0001). Median number of treatment cycles was nine for Vidaza.
The survival benefits of Vidaza were consistent regardless of the CCR treatment option (best supportive care (BSC) alone, low-dose cytarabine plus BSC or standard chemotherapy plus BSC) utilized in the control arm.
"These landmark results, showing a significant improvement in survival in the most advanced MDS patients, validate the benefit Vidaza can provide patients with this extremely difficult to treat disease," said Dr. Lewis R. Silverman, Associate Professor of Medicine, Division of Hematology and Medical Oncology, Mount Sinai School of Medicine. "Building on the established data from our earlier clinical studies, which showed that Vidaza offers transfusion independence to many patients with MDS, we now see that Vidaza not only improves a patient's life, but extends it as well."
"With these very exciting results for Vidaza, survival should now be the standard by which we evaluate treatment options for higher-risk MDS," said Dr. Alan F. List, Chief, Malignant Hematology Division and Deputy Physician in Chief, H. Lee Moffitt Cancer Center and Research Institute. "Importantly, as the first and only epigenetic therapy to have demonstrated a survival benefit in any cancer, these findings should accelerate exploration of Vidaza in other malignancies where hypermethylation is believed to play a key role in tumor development and progression."
"We are extremely gratified with the results from the Vidaza Survival Study, which for the first time bring the hope of prolonged survival for patients with higher-risk MDS," said Patrick J. Mahaffy, Pharmion's chief executive officer and president. "As the only therapy to have ever demonstrated a survival advantage in MDS, and especially to have demonstrated an improvement of this magnitude, Vidaza is unique in the treatment for this disease."
Pharmion expects to present full study results at an upcoming medical meeting. Based on these results, Pharmion intends to file a Marketing Authorization Application (MAA) in the European Union (EU) for Vidaza for the treatment of higher-risk MDS before the end of this year and will shortly thereafter submit additional international regulatory submissions. The Company will also file a supplemental New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) to include these data in the prescribing information in the U.S.
Pharmion is also developing a next generation product, oral Azacitidine, for the treatment of MDS and other cancers where demethylation can provide an anti-tumor effect. Oral Azacitidine is the subject of a Phase 1 multi-center, open label dose escalation trial that will assess the maximum tolerated dose, dose limiting toxicities and safety of a seven day, multi-cycle oral dosing regimen of oral Azacitidine in patients with MDS and AML. In addition, the trial will examine pharmacokinetics and pharmacodynamic effects of orally administered Azacitidine, as compared with parenteral Vidaza.
Pharmion will hold a conference call to discuss these results later this morning, August 2, at 9:00 a.m. ET. The conference call will be simultaneously webcast on the Company's web site at www.pharmion.com, and archived for future review. Dial-in numbers for the conference call for institutional investors and analysts are as follows: participants from the U.S. 866.314.5232, International participants 617.213.8052, passcode: 71992680.
About the Trial Design
I think DYII is good for a long position here - pullback has been modest and on tiny volume. Possibly will put in a buy stop above todays high. Just thinking out loud here.
s/be that guy
Still don't get why people buy/sell before the bell pre earnings.
Lottery ticket? Looks like the AMZN ticket was real expensive if that got got short at the close.
Thanks for the reply, it probably will have triple the volume tomorrow!
Nice grab Eagle, you think it has more to go? Considering a short position in AH. Not too sure though.
.051 is what the RS would be based on? Have I found some brain cells? I couldn't locate anywhere in the filing what the split price was based on.
Mind showing me your math? I'm having some trouble - too long of a work day maybe.
1 share @ .51
100-1 RS price of $51 (100 x .51)
100 sh @ 51 = $5100
Any help from anyone would be helpful. TIA
Was in and out for small cash eod, the spread was way too big for my liking (.30 at times when the volume came in) and i chickened out :(
SBEI on a tear!eom
BIDU within reach of $200 eom
LOCM on the move - big time eom
nevermind "trying" to go eom
HOKU trying to go
Awesome trade eagle, looks as though it still got juice! gl
MOVI beatdown in pre.eom
EVCI, one to watch, pull up a 1 year chart :)